title: [Comparative assessment of fluoroquinolones efficacy in the treatment of patients with infectious exacerbation of chronic obstructive bronchitis].
abstract: Moxyfloxacinum in a dose of 400 mg daily in tablets over 5 days proved to have good results in 92,7% of patients with infectious exacerbation of chronic obstructive bronchitis type I. Cyprofloxacin in a dose of 500 mg every 12 hours over 7 days had positive effects in 78,6%. Thus, the using of fluoroquinolones in patients with infectious exacerbation of chronic obstructive bronchitis type I gives sufficiently good results. It allows us to use Moxyfloxacinum as a drug of choice in treatment of patients with this disease.
authors.forename: L V
authors.initials: LV
authors.lastname: Iudina
authors.forename: V I
authors.initials: VI
authors.lastname: Snezhko
authors.forename: Iu V
authors.initials: IuV
authors.lastname: Rachko
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001372:Aza Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology; D029481:Bronchitis, Chronic / Q000188:drug therapy* / Q000382:microbiology; D002939:Ciprofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D024841:Fluoroquinolones; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077266:Moxifloxacin; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D002939:Ciprofloxacin; D000077266:Moxifloxacin